P50613 (CDK7_HUMAN) Homo sapiens (Human)

Cyclin-dependent kinase 7 UniProtKBInterProSTRINGInteractive Modelling

346 aa; Sequence (Fasta) ; 5 identical sequences: Homo sapiens: A0A0S2Z3F9; Pan troglodytes: A0A2I3S9X0, A0A6D2WVT0; Pan paniscus: A0A2R8ZZV4; Gorilla gorilla gorilla: G3RC03

Available Structures

32 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
TFIID-based holo PIC on SCP promoter Heteromer
A0A481BYI6; A0A4X1TRS6; A0A4X1TVZ5; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VTX4; F1RKE4; I3LCB2; I3LCH3; O00268; P13984; P18074; P19447; P20226; P21675; P24928; P29083; P29084; P32780; P35269; P49848; P51946; P51948; P52655; P52657; P60899; Q00403; Q12962; Q13888; Q13889; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q6ZYL4; Q7Z7C8; Q92759;
10-312
17×ZN;SF4;MG;
Assess
Human Mediator with RNA Polymerase II Pre-initiation complex Heteromer
A0A287ADR4; A0A4X1TRS6; A0A4X1VEK9; A0A4X1VYD0; A0A7M4DUC2; A0JLT2; F1RKE4; I3LCB2; I3LCH3; I3LGP4; I3LSI7; O43513; O60244; O75586; P13984; P18074; P19447; P20226; P29083; P29084; P32780; P35269; P51946; P51948; P52655; P52657; P60899; Q00403; Q13503; Q13888; Q13889; Q15528; Q6P2C8; Q6ZYL4; Q92759; Q96G25; Q96HR3; Q9BTT4; Q9BUE0; Q9H204; Q9H944; Q9NPJ6; Q9NVC6; Q9NWA0; Q9P086; Q9Y3C7;
10-312
SF4; 18×ZN;MG;
Assess
Cryo-EM structure of CAK-THZ1 Heteromer
P51946; P51948;
10-312
V0G;
Assess
Structure of the human CDK-activating kinase Heteromer
P51946; P51948;
10-312
MG;AGS;
Assess
Structure of the human CAK in complex with THZ1 Heteromer
P51946; P51948;
10-312
V0G;
Assess
Structure of the human Mediator-bound transcription pre-initiation complex Heteromer
A0JLT2; O15514; O43513; O60244; O75448; O75586; P13984; P18074; P19387; P19388; P19447; P20226; P24928; P29083; P29084; P30876; P32780; P35269; P36954; P51946; P51948; P52434; P52435; P52655; P52657; P53803; P61218; P62487; P62875; Q00403; Q13503; Q13888; Q13889; Q15528; Q6P2C8; Q6ZYL4; Q71SY5; Q92759; Q96G25; Q96HR3; Q96RN5; Q9BTT4; Q9BUE0; Q9H204; Q9H944; Q9NPJ6; Q9NVC6; Q9NWA0; Q9NX70; Q9P086; Q9ULK4; Q9Y2X0; Q9Y3C7;
10-312
MG; 16×ZN;SF4;
Assess
Cryo-EM structure of the human CAK bound to ICEC0942 (PHENIX-OPLS3e) Heteromer
P51946; P51948;
10-311
I74;
Assess
Cryo-EM structure of the human CAK bound to ICEC0942 at 2.5 Angstroms resolution Heteromer
P51946; P51948;
10-311
I74;
Assess
Cryo-EM structure of CDK7 subunit of CAK in complex with inhibitor LDC4297 Heteromer
P51948;
10-311
WD9;
Assess
Cryo-EM structure of CAK in complex with nucleotide analogue ATPgS Heteromer
P51946; P51948;
10-310
AGS;MG;
Assess
Cryo-EM structure of CAK in complex with inhibitor ICEC0942 Heteromer
P51946; P51948;
10-310
I74;
Assess
Cryo-EM structure of CAK in complex with inhibitor ICEC0880 (ring-up conformation) Heteromer
P51946; P51948;
10-310
X3Z;
Assess
Cryo-EM structure of CAK in complex with inhibitor ICEC0880 (ring-down conformation) Heteromer
P51946; P51948;
10-310
X3Z;
Assess
Cryo-EM structure of CAK in complex with inhibitor ICEC0914 Heteromer
P51946; P51948;
10-310
X1W;
Assess
Cryo-EM structure of CAK in complex with inhibitor ICEC0510-S Heteromer
P51946; P51948;
10-310
X4Q;
Assess
Cryo-EM structure of CAK in complex with inhibitor CT7030 Heteromer
P51946; P51948;
10-310
ZQ6;
Assess
Cryo-EM structure of CAK in complex with inhibitor ICEC0943 Heteromer
P51946; P51948;
10-310
I73;
Assess
Cryo-EM structure of CAK in complex with inhibitor dinaciclib Heteromer
P51946; P51948;
10-310
1QK;
Assess
Cryo-EM structure of CAK in complex with inhibitor ICEC0574 Heteromer
P51946; P51948;
10-310
X4F;
Assess
Cryo-EM structure of CAK in complex with inhibitor BS-181 Heteromer
P51946; P51948;
10-310
X2H;
Assess
Cryo-EM structure of CAK in complex with inhibitor ICEC0510-R Heteromer
P51946; P51948;
10-310
X4L;
Assess
Cryo-EM structure of CAK in complex with inhibitor ICEC0768 Heteromer
P51946; P51948;
10-310
X2Z;
Assess
Cryo-EM structure of CAK in complex with inhibitor ICEC0829 Heteromer
P51946; P51948;
10-310
X50;X58;
Assess
Cryo-EM structure of CAK in complex with inhibitor BS-194 Heteromer
P51946; P51948;
10-310
NS9;
Assess
Cryo-EM structure of CAK with averaged inhibitor density Heteromer
P51946; P51948;
10-310
Assess
RNA polymerase II pre-initiation complex with the distal +1 nucleosome (PIC-Nuc18W) Heteromer
A0A287ADR4; A0A4X1TRS6; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VYD0; A0A7M4DUC2; F1RKE4; I3LCB2; I3LCH3; I3LGP4; I3LSI7; P02281; P06897; P13984; P18074; P19447; P20226; P29083; P29084; P32780; P35269; P51946; P51948; P52655; P52657; P60899; P62799; P84233; Q00403; Q13888; Q13889; Q6ZYL4; Q92759;
13-311
SF4; 17×ZN;MG;
Assess
Human holo-PIC in the closed state Heteromer
O15514; P13984; P18074; P19387; P19388; P19447; P20226; P23193; P24928; P29083; P29084; P30876; P32780; P35269; P36954; P51946; P51948; P52434; P52435; P52655; P52657; P53803; P61218; P62487; P62875; Q00403; Q13888; Q13889; Q6ZYL4; Q92759;
13-311
MG; 17×ZN;SF4;
Assess
RNA polymerase II pre-initiation complex with the proximal +1 nucleosome (PIC-Nuc10W) Heteromer
A0A287ADR4; A0A4X1TRS6; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VYD0; A0A7M4DUC2; F1RKE4; I3LCB2; I3LCH3; I3LGP4; I3LSI7; P02281; P06897; P13984; P18074; P19447; P20226; P29083; P29084; P32780; P35269; P51946; P51948; P52655; P52657; P60899; P62799; P84233; Q00403; Q13888; Q13889; Q6ZYL4; Q92759;
13-310
SF4; 16×ZN;MG;
Assess
p53-bound TFIID-based holo PIC on HDM2 promoter Heteromer
A0A481BYI6; A0A4X1TRS6; A0A4X1TVZ5; A0A4X1VEK9; A0A4X1VKG7; A0A4X1VTX4; F1RKE4; I3LCB2; I3LCH3; O00268; P13984; P18074; P19447; P20226; P21675; P24928; P29083; P29084; P32780; P35269; P49848; P51946; P51948; P52655; P52657; P60899; Q00403; Q12962; Q13888; Q13889; Q15542; Q15543; Q15544; Q15545; Q16514; Q16594; Q5VWG9; Q6P1X5; Q6ZYL4; Q7Z7C8; Q92759;
13-310
16×ZN;SF4;MG;
Assess
Crystal structure of the dual T-loop phosphorylated Cdk7/CycH/Mat1 complex Heteromer
P51946; P51948;
46-311
EDO;
Assess
Crystal structure of the human CDK7 kinase domain in complex with LDC4297monomer11-310
WZ8;GOL;PGE;
Assess
Crystal Structure of Human CDK7monomer13-311
ATP;
Assess

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
7lbm.1.8monomer0.8110-312
100.00
Assess